AI Article Synopsis
- - Parkinson's Disease (PD) can be tough to distinguish from related disorders like Progressive Supranuclear Palsy and Corticobasal Syndrome, and there's a need for better diagnostic biomarkers.
- - A study analyzed plasma from 148 people (including those with PD, 4R-Tauopathies, and healthy controls) and found lower levels of complement proteins C1q and C3 in those with 4R-Tauopathies compared to both PD and healthy controls.
- - While complement levels and activity didn’t show major differences between PD patients and healthy individuals, some complement proteins correlated with PD symptom severity, especially C3 with non-motor symptoms in women.
Article Abstract
Parkinson's Disease (PD) is diagnosed clinically, and early PD is often challenging to differentiate from atypical parkinsonian disorders such as the Four-repeat (4R-) Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome. Diagnostic biomarkers are needed, and proteomic studies have suggested that the plasma complement system is altered in PD, but validation studies are lacking. In this study, plasma from 148 individuals (PD, 4R-Tauopathies, and healthy controls (HC)) were used to quantify 12 complement proteins with immunoassays, and CH50 classical pathway complement activity was quantified in sera from further 78 individuals (PD and HC). Complement factors C1q and C3 in plasma were lower in individuals with 4R-Tauopathies (ANOVA, p = 0.0041, p = 0.0057 respectively) compared to both PD and HC. None of the complement proteins were altered between PD and HC, however a few proteins correlated with clinical parameters within the PD group. Notably, levels of C3 correlated with non-motor symptoms in female patients. Classical pathway complement activity was not altered in PD serum, but did correlate with mental fatigue. In conclusion, individuals with 4R-Tauopathies showed lower plasma C1q and C3 compared PD and HC. Neither complement levels nor CH50 activity were significantly altered in PD versus HC but may associate with PD symptom severity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.parkreldis.2023.105313 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies.
Acta Neuropathol
November 2024
Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilian University of Munich, Marchioninstraße 15, 81377, Munich, Germany.
Tau PET has attracted increasing interest as an imaging biomarker for 4-repeat (4R)-tauopathy progressive supranuclear palsy (PSP). However, the translation of in vitro 4R-tau binding to in vivo tau PET signals is still unclear. Therefore, we performed a translational study using a broad spectrum of advanced methodologies to investigate the sources of [F]PI-2620 tau PET signals in individuals with 4R-tauopathies, including a pilot PET autopsy study in patients.
View Article and Find Full Text PDFMicroscopy assessment of a fluorescence [F] flortaucipir analog (T726) shows neuropathological overlap with 3R and 4R tau lesions.
Alzheimers Dement
December 2024
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Article Synopsis
- The study investigates the binding of a fluorescent analog of flortaucipir (T726) to different tau proteins in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD).
- T726 showed significant co-localization with PHF tau in AD but had limited interaction with 3R and 4R tau lesions in FTLD.
- Findings suggest that while T726 binds to some FTLD tau lesions, it doesn't bind to all, indicating the need for further research to understand the varying binding patterns.
Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.
Alzheimers Dement
October 2024
Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, München, Germany.
Introduction: Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker-based workflows to assess 4R-tauopathy (4RT) patients are currently missing. We suggest a novel biomarker-based algorithm to characterize AD and 4RTs.
Methods: We cross-sectionally assessed combinations of cerebrospinal fluid measures (CSF p-tau and t-tau) and F-PI-2620 tau-positron emission tomography (PET) in patients with AD (n = 64), clinically suspected 4RTs (progressive supranuclear palsy or corticobasal syndrome, n = 82) and healthy controls (n = 19).
Neuroinflammation Parallels 18F-PI-2620 Positron Emission Tomography Patterns in Primary 4-Repeat Tauopathies.
Mov Disord
September 2024
Institute for Stroke and Dementia Research, LMU Munich, Munich, Germany.
Background: Preclinical, postmortem, and positron emission tomography (PET) imaging studies have pointed to neuroinflammation as a key pathophysiological hallmark in primary 4-repeat (4R) tauopathies and its role in accelerating disease progression.
Objective: We tested whether microglial activation (1) progresses in similar spatial patterns as the primary pathology tau spreads across interconnected brain regions, and (2) whether the degree of microglial activation parallels tau pathology spreading.
Methods: We examined in vivo associations between tau aggregation and microglial activation in 31 patients with clinically diagnosed 4R tauopathies, using 18F-PI-2620 PET and 18F-GE180 (translocator protein [TSPO]) PET.
Subcortical tau is linked to hypoperfusion in connected cortical regions in 4-repeat tauopathies.
Brain
July 2024
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany.
Article Synopsis
- Four-repeat tauopathies are brain diseases that happen when a protein called 4R tau builds up in certain areas of the brain, affecting how it works.
- Two main types of these diseases are progressive supranuclear palsy (PSP) and corticobasal degeneration, which both cause problems in brain regions that are important for movement and other functions.
- The researchers are trying to figure out how the problems in one part of the brain (subcortical) affect other connected areas (cortical) by studying patients and using special brain scans to see how these changes relate to each other.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!